Concentrations of vatinoxan and xylazine in plasma, cerebrospinal fluid and brain tissue following intravenous administration in sheep

Vet Anaesth Analg. 2021 Nov;48(6):900-905. doi: 10.1016/j.vaa.2021.08.003. Epub 2021 Aug 28.

Abstract

Objectives: To investigate the extent of vatinoxan distribution into sheep brain, and whether vatinoxan influences brain concentrations of xylazine; and to examine the utility of cerebrospinal fluid (CSF) as a surrogate of brain tissue concentrations for vatinoxan and xylazine.

Study design: Randomised, blinded, experimental study.

Animals: A total of 14 adult female sheep.

Methods: Sheep were randomly allocated into two equal groups and premedicated with either intravenous (IV) vatinoxan (750 μg kg-1, VX) or saline (SX) administered 10 minutes before IV xylazine (500 μg kg-1). Sedation was subjectively assessed at selected intervals before and after treatments. At 10 minutes after xylazine administration, a venous blood sample was collected and the sheep were immediately euthanised with IV pentobarbital (100 mg kg-1). Plasma, CSF and brain tissues were harvested, and concentrations of vatinoxan and xylazine were quantified using liquid chromatography-tandem mass spectrometry. Drug ratios were then calculated and the data were analysed as appropriate.

Results: The brain-to-plasma and CSF-to-plasma ratios of vatinoxan were 0.06 ± 0.013 and 0.05 ± 0.01 (mean ± standard deviation), respectively. Xylazine brain concentrations were not significantly different (835 ± 262 versus 1029 ± 297 ng g-1 in groups VX and SX, respectively) and were approximately 15-fold higher than those in plasma. The CSF-to-brain ratio of vatinoxan was 0.8 ± 0.2, whereas xylazine concentrations in the brain were approximately 17-fold greater than those in CSF, with and without vatinoxan.

Conclusions and clinical relevance: Vatinoxan did not significantly affect sedation with xylazine or the concentrations of xylazine in the brain. CSF is not a good predictor of xylazine concentrations in the brain, whereas vatinoxan concentrations were concordant between the brain and CSF, using the dosages in this study.

Keywords: MK-467; brain tissue; cerebrospinal fluid; sheep; vatinoxan; xylazine.

Publication types

  • Randomized Controlled Trial, Veterinary

MeSH terms

  • Administration, Intravenous / veterinary
  • Animals
  • Brain
  • Female
  • Pharmaceutical Preparations*
  • Quinolizines
  • Sheep*
  • Xylazine*

Substances

  • Pharmaceutical Preparations
  • Quinolizines
  • Xylazine
  • vatinoxan